(Fort Worth, TX) --- H. Paul Dorman, Chairman and CEO of Fort Worth-based DFB Pharmaceuticals, Inc., has announced that DFB has promoted Duncan Aust, Ph.D. to Senior Vice President of Research and Development, Branded Pharmaceuticals, a newly-created position for DFB. Dr. Aust was most recently Vice President of DPT Research and Development, a DFB affiliate headquartered in San Antonio.

        The new position was created to coordinate, manage and cross-leverage DFB’s assets by focusing on the needs of its branded product companies.

        “Dr. Aust has proven to be a talented research leader, with the necessary scholastic background and many years of experience in our areas of interests, in both pharmaceutics and biologics,” Mr. Dorman stated. “We believe that he will be able to build upon his relationships and knowledge of the DPT research organization to enhance synergy in the continued development of our branded business.”

        Dr. Aust graduated from King’s College London (University of London) in 1994 with a Ph.D. in Biotechnology. After graduating, Dr. Aust began his career as the Director of Development & Special Analytical Services with the Collaborative Group in New York, where he was a key contributor to manufacturing, production and new business development needs.

        Dr. Aust joined DFB-affiliate DPT Research and Development in 2002.

        DFB Pharmaceuticals Inc. is a privately held Texas corporation that provides technology-driven pharmaceutical products, outsourcing services, and licensing opportunities through its affiliate partners to the healthcare industry worldwide. DFB affiliates include HEALTHPOINT, active in the research, development, and marketing of branded pharmaceuticals, over-the-counter drugs, and biotech drugs for tissue management and surgical indications since 1992; Coria Laboratories, focusing in dermatology and treatments of diseases that affect the skin, hair, and nails; DPT Laboratories, Ltd., a leading outsourcing service organization that develops and manufactures semi-solids, liquids, nasal spray, aerosol foam and complex delivery forms, for the pharmaceutical industry; Phyton Biotech, Inc., whose proprietary plant cell culture technology platform is used to develop and manufacture products with applications in the pharmaceutical and biotech industries, with a German subsidiary, Phyton GmbH, that operates the world’s largest commercial cGMP manufacturing facility for plant cell fermentation; and DFB Bioscience, focusing on cell based therapeutic research and development.

        DFB currently has 1700 employees worldwide. DFB is on the web at www.dfb.com.

###